Investigating a protein's role in neurodegenerative diseases like ALS and frontotemporal dementia
Official title: Exploring TMEM106B in Neurodegeneration: Protein Interaction and Fibril-induced Neurotoxicity
Funded at Emory University · NIH-10952583 · Data updated 2026-11-12
This study is looking at how a protein called TMEM106B interacts with certain genetic changes linked to frontotemporal dementia and ALS, hoping to find new ways to help people with these conditions in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $52,082 |
| NIH project number | 1R36AG088283-01 |
| Project ID | NIH-10952583 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with frontotemporal dementia or amyotrophic lateral sclerosis, particularly those with C9orf72 gene mutations.
✕Less likely to help
Patients with neurodegenerative diseases not related to the C9orf72 gene or those without significant cognitive impairment may not benefit from this research.
What this research studies
This research focuses on understanding how the TMEM106B protein interacts with genetic mutations associated with neurodegenerative diseases, particularly in patients with frontotemporal dementia and amyotrophic lateral sclerosis (ALS). The study will explore the relationship between TMEM106B and a specific dipeptide repeat protein produced by mutations in the C9orf72 gene. By examining these interactions, researchers aim to uncover mechanisms that lead to neurotoxicity and cognitive decline. Patients may benefit from insights that could inform future treatments or interventions for these conditions.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for patients suffering from neurodegenerative diseases.
How similar studies have gone: Previous research has shown promising results in understanding the genetic factors contributing to neurodegeneration, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Tilahun, Kedamawit — Emory University
- Study coordinator: Tilahun, Kedamawit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.